Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from.

Slides:

Advertisements

Similar presentations

Iron Overload in Chronic Anaemias Dick Wells MD, DPhil, FRCPC Director, Crashley Myelodysplastic Syndrome Research Laboratory.

Advertisements

Brown JR et al. Proc ASH 2013;Abstract 523.

1 Rash and Low T2* MRI in a Paediatric Thalassaemia Patient.

Clinical Case: Managing Iron Overload in a Patient with Transfusion- Independent Thalassaemia Intermedia Ali T. Taher, MD Professor Department of Internal.

Slide 1 of 16 Dose Titration in a Patient with Myelodysplastic Syndromes.

Managing Iron Overload in Beta Thalassemia Major: Focus on Cardiac Iron Ali Taher, MD American University of Beirut Lebanon.

Effect of Hepatic Impairment on Sorafenib Pharmacokinetics: Results of a Multicenter, Open-Label, Single-Dose, Phase I Trial J Lettieri, A Mazzu,

Noncompliance with Iron Chelation Therapy in an Adolescent with Thalassaemia Major Adlette C. Inati, MD Head, Division of Pediatric Hematology-Oncology.

Controversies in Iron Chelation in Myelodysplastic Syndromes

Results of a Phase II Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post- Essential.

Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.

Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cortes JE et al. Proc ASH 2013;Abstract 1483.

Clinical Considerations for Managing Iron Overload in MDS: Analysis From EHA Aristoteles Giagounidis, MD, PhD Associate Professor of Medicine Head, Hematology/Oncology.

Slide 1 of 26 Iron Chelator Basics Ali T. Taher, MD Professor of Medicine Haematology-Oncology Division American University Beirut Medical Center Beirut,

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.

A Double-Blind, Randomized, Placebo-Controlled Trial of High- Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole- Treated.

Mariane de Montalembert, MD

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

11 One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor A Randomized Trial Joensuu H, Eriksson M, Sundby Hall K, et al.

Cardiac Effects of Iron Overload

Carla Chieffo, VMD, PhD, 1 Lawrence A. Frohman, MD, 2 Harry Quandt, BS, 1 Stefanie Decker, MS, 1 Mônica R. Gadelha, MD, PhD 3 1 Endo Pharmaceuticals Inc.,

A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

CE-1 Exjade ® (deferasirox; ICL670) Efficacy and Safety Peter Marks, MD, PhD Senior Director, Clinical Development Novartis Pharmaceuticals Corporation.

An Ongoing Phase 3 Study of Bosutinib (SKI-606) versus Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Gambacorti-Passerini.

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase.

CB-1 MDS Classification and Prognosis John M. Bennett, MD University of Rochester Medical Center Hematomorphologist Chair, MDS Foundation.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

OFEV ® (nintedanib) safety Safety data INPULSIS ® -1 & -2 These slides are provided by Boehringer Ingelheim for medical to medical education only. Last.

Locatelli F et al. Proc ASH 2013;Abstract 4378.

 Treatment regimens –Co-formulated ombitasvir (OBV)/paritaprevir (PTV)/rironavir (r) : 25/150/100 mg QD = 2 tablets –Dasabuvir (DSV) : 250 mg BID –RBV.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve- Month Efficacy and Safety.

Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36

A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates.

CS-1 Lenalidomide Safety Assessment Study MDS-003, 002 Robert Knight, MD Vice President Clinical Research Oncology Celgene Corporation.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-Up Update Cortes.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Thalassemia Center 1 Iron Overload in Chronic Anaemias.

Exjade One Year Experience Dr Khawla Belhoul Director Thalassemia Center 9 Th February 2008.

ANCO 2006 ASH UPDATE MDS Joseph M. Tuscano, M.D. UC Davis Cancer Center.

POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.

At least one mobile phone will ring during a meeting or concert Anything that can go wrong will go wrong.

1 Oliva EN et al Proc ASH 2015;Abstract 91.

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced

Gajria D et al. Proc SABCS 2010;Abstract P

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Neal B, et al. Diabetes Care 2015;38:403–411

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Cortes JE et al. Proc ASCO 2010;Abstract 6502.

Phase 2 Treatment Naïve Injection Drug Use

Kantarjian H et al. Cancer 2009;[Epub ahead of print].

Barrios C et al. SABCS 2009;Abstract 46.

Phase 3 Treatment Naïve HIV Coinfection

Krop I et al. SABCS 2009;Abstract 5090.

N3-378 Template 12/31/2018 7:52 PM 8 8.

Lyons RM et al. J Clin Oncol 2009;27(11):

1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.

Advani RH et al. Proc ASH 2011;Abstract 443.

NGM282 in NASH: 3 mg vs 6 mg QD (phase 2)

Clinical Case: Managing Iron Overload in a Patient with Transfusion-Independent Thalassaemia Intermedia Ali T. Taher, MD Professor Department of Internal.

Phase 3 Treatment-Naïve and Treatment-Experienced

Kantarjian HM et al. Blood 2008;112:Abstract 635.

Presentation transcript:

Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial1 Iron Chelation with Deferasirox Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)2 1Gattermann N et al. Blood 2008;112: Abstract 633. 2List AF et al. Blood 2008;112: Abstract 634.

Introduction Many patients with myelodysplastic syndromes (MDS) are susceptible to iron overload from ongoing blood transfusions and increased dietary iron absorption. Deferasirox has demonstrated efficacy in maintaining or reducing body iron in patients with MDS. The EPIC1 and US032 studies evaluated efficacy and safety of deferasirox in patients with MDS: Primary endpoint: change in serum ferritin (SF) from baseline at 12 months Safety was assessed by laboratory parameters and adverse events monitoring Source: 1Gattermann N et al. Blood 2008;112:Abstract 633; 2List AF et al. Blood 2008;112:Abstract 634.

EPIC: Multicenter, Open-Label, Single-Arm Study of Deferasirox in Patients with Anemia, including MDS Eligibility Transfusion-dependent MDS; serum ferritin (SF) > 1000 ng/ml or < 1000 ng/ml and requiring >20 transfusions or 100 mL/kg blood; MRI-confirmed liver iron concentration >2 mg Fe/g dry weight Treatment (n=341) Initial dose: deferasirox, 10-30 mg/Kg/day for 12 months SF assessed q mo; dose adjusted according to protocol specifications in 5-10 mg/kg/d steps q 3 mo based on SF trends and safety markers Source: Gattermann N et al. Blood 2008;112:Abstract 633.

US03: Multicenter, Open-Label Study of Deferasirox in Patients with MDS Eligibility Transfusion-dependent Low- or Int-1 IPSS-risk MDS; serum ferritin (SF) > 1000 ng/ml and requiring >20 units RBC transfusions; Serum creatinine (SCr) < 2 x upper limit of normal (ULN) Treatment (n=176) Initial dose: deferasirox, 20 mg/Kg/day, increased to 40 mg/Kg/day based on tolerability and response • SF assessed q mo and labile plasma iron (LPI) assessed quarterly Source: List AF et al. Blood 2008;112:Abstract 634.

Deferasirox for MDS: Reduction in Serum Ferritin (SF) from Baseline Over 1 Year Month Median SF (ng/mL) EPIC1 (n=341) US032 (n=176) 0 (baseline) 2730 3397 3 2358 3057 6 2210 2802 9 2076 2635 12 1904 2501 1EPIC: Change in median SF over one year by last observation carried forward with all patients included: -253 ng/mL (p=0.0019) 2US03: At 3 mos, sustained suppression of labile plasma iron (LPI) to within normal range was achieved in patients with baseline levels (41% of patients had elevated LPI at baseline) Source: 1Gattermann N et al. Blood 2008;112:Abstract 633; 2List AF et al. Blood 2008;112:Abstract 634.

Deferasirox for MDS: Most Common Drug-Related Adverse Events Adverse Events (AE) Patients, n (%) EPIC1 (n=341) US032,3 (n=165) Diarrhea 110 (32%) 71 (43%) Nausea 45 (13%) 29 (18%) Vomiting 26 (8%) not reported Abdominal pain1/distension3 51 (15%) 9 (6%) Serum creatinine >ULN for >2 values 36 (10.6%) 26* (18%) Rash 23 (7%) 14 (9%) Constipation 21 (6%) *Patients with normal baseline creatinine (n=147) Discontinuation of drug due to drug-related AEs: 13%(EPIC)1, 10% (US03)2 Source: 1Gattermann N et al. Blood 2008;112:Abstract 633; 2List AF et al. Blood 2008;112:Abstract 634; 3Sekeres MA. Oncology Congress 2009 Presentation HM107.

Conclusions Deferasirox provided significant reduction in SF levels over 1-year of treatment with appropriate dose adjustments based on SF trends and safety markers Primary Reduction in mean SF (EPIC1): -253 ng/mL, p=0.0019 Reduction in LPI levels after 3 months to normal range (US032) The adverse events reported were mild to moderate and consistent with previously reported deferasirox data in patients with MDS Diarrhea (32 - 43%) Increase in creatinine to >ULN for at least 2 values (EPIC1:10.6%; US032:18%) Source: 1Gattermann N et al. Blood 2008;112:Abstract 633; 2List AF et al. Blood 2008;112:Abstract 634.